Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GSK), Karyopharm Therapeutics (KPTI) and Eyenovia (EYEN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GlaxoSmithKline (GSK – Research Report), Karyopharm Therapeutics (KPTI – Research Report) and Eyenovia (EYEN – Research Report).

GlaxoSmithKline (GSK)

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline yesterday and set a price target of p1450.00. The company’s shares closed last Tuesday at $36.78.

According to TipRanks.com, Parry is a 3-star analyst with an average return of 4.9% and a 60.9% success rate. Parry covers the Healthcare sector, focusing on stocks such as Haleon PLC Sponsored ADR, Gilead Sciences, and Novartis.

Currently, the analyst consensus on GlaxoSmithKline is a Moderate Sell with an average price target of $19.66.

See Insiders’ Hot Stocks on TipRanks >>

Karyopharm Therapeutics (KPTI)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Karyopharm Therapeutics today and set a price target of $16.00. The company’s shares closed last Tuesday at $4.15.

According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.1% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Inhibikase Therapeutics, and Syndax Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karyopharm Therapeutics with a $10.25 average price target, an 120.0% upside from current levels. In a report issued on April 6, RBC Capital also maintained a Buy rating on the stock with a $6.00 price target.

Eyenovia (EYEN)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Eyenovia today and set a price target of $12.00. The company’s shares closed last Tuesday at $4.44, close to its 52-week high of $4.92.

According to TipRanks.com, Caufield is a 5-star analyst with an average return of 62.8% and a 77.3% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, 4D Molecular Therapeutics, and Aldeyra Therapeutics.

Currently, the analyst consensus on Eyenovia is a Moderate Buy with an average price target of $12.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GSK:

• Bellus Health Surges after Acquisition by GSK for $2 Billion
• GSK reports EAGLE-2 and EAGLE-3 phase III trials met primary endpoint
• Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
• Adaptimmune taking back PRAME and NY-ESO target programs from GSK
• GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says